Oncology

Zilovertamab vedotin

Merck (MSD)

ROR1-directed ADC. waveLINE-010 Phase 3 (1L DLBCL, ZV + R-CHP vs R-CHOP) enrolling globally. Phase 2 showed 100% CR rate at RP2D.

Diffuse Large B-Cell Lymphoma1st-line

Linked Studies

NCT06717347PrimaryRECRUITINGPHASE3

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Diffuse Large B-Cell LymphomaUpdated May 2026

Loading comments…

Also Known As

Other names

zilovertamab

Search all trials →Request coverage update